Price History

Hover for the daily close. The dotted line marks the period open.

Compare ICU with… →

ICU Key Statistics

As of Sep 4, 2026

Trading

Open: $2.84
Previous Close: $2.91
Day's Range: 2.84–3.01
52-Week Range: 2.07–12.50
Volume: 25.50K
Beta: −1.03

Valuation

Market Cap: $13.13M
P/E Ratio: unprofitable
P/S ratio: 7.67
EPS (ttm): −1.94

Financials (FY)

Revenue (FY): $1.23M+814.07%
Net Income (FY): −$12.15M
Profit margin: 0.00%
Shares Outstanding: 4.41M
1-Year Return: −63.61%

Dividend and dates

Avg Volume: 85.51K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ICU Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+2.45%−59.16%−89.20%−82.48%−87.63%+24.17%

2021*20222023202420252026*

Year	Return
2026 (partial year)	+24.17%
2025	−87.63%
2024	−82.48%
2023	−89.20%
2022	−59.16%
2021 (partial year)	+2.45%

As of September 4, 2026.

ICU Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$1.23M	−$12.15M	−984.6%
2024	$135.00K	−$24.83M	−18392.6%
2023	$0.00	−$26.23M	—
2022	$0.00	−$12.19M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$1.23M	$1.18M	−$12.18M	−$12.15M	−984.6%
2024	$135.00K	$135.00K	−$17.84M	−$24.83M	−18392.6%
2023	$0.00	$0.00	−$14.21M	−$26.23M	—
2022	$0.00	—	−$11.61M	−$12.19M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ICU Valuation vs Biotechnology Median

Median of 656 stocks

Metric	ICU	Biotechnology median	vs median
P/S ratio	7.67	15.26	50% below
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript
SeekingAlpha2026-08-12

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values SeaStar Medical Holding Corporation (ICU) at $13.13M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 18.

ICU last closed at $2.98 on September 4, 2026. That is +$0.07 (+2.41%) against the previous close. Over the past 52 weeks the price has ranged from $2.07 to $12.50. The latest close sits 43.96% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.23M. That is +814.07% against the prior fiscal year, when revenue was $135.00K. The same year closed with a net loss of $12.15M. The reported profit margin is 0%. Trailing earnings per share are −1.94.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $1.23M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 7.67 times revenue. On price-to-sales that is 49.78% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −63.61%. Measured over 5 years, that is −73.95% a year compounded. Beta against the wider market is reported at −1.03. Daily returns over the trailing 5 years annualize to a volatility of 131.6%.

Growth & Income

No dividend is on file for ICU.

2026 is still running; the price is +24.17% year to date. The strongest complete calendar year on file is 2022 at −59.16%; the weakest is 2023 at −89.20%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

SeaStar Medical Holding Corporation (ICU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
SeaStar Medical Holding Corporation	ICU	$13.13M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. SeaStar Medical Holding Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Visit website →

SeaStar Medical Holding Corporation (ICU) Stock Analysis